LIF

Leukemia inhibitory factor (LIF) is a cytokine which belongs to the IL-6 superfamily. LIF derives its name from its ability to inhibit proliferation of myeloid leukemia cells in culture. Currently, LIF expression has been found in activated T cells, monocytes, glial cells, liver fibroblasts, bone marrow stromal cells, embryonic stem cells, thymic epithelial cells and many other cells. It is an interleukin 6 class cytokine that affects cell growth by inhibiting differentiation. LIF action appears to be mediated through a high-affinity receptor complex composed of a low-affinity LIFRβ (also known as LIFR) and a high-affinity converter subunit, gp130. LIFRβ is a single pass transmembrane domain-containing protein and is the tallest of the "tall" cytokine receptors, containing eight distinct domains in its extracellular segment.

LIF, a cytokine with a variety of functions, is involved in the induction of hematopoietic differentiation in normal and myeloid leukemia cells, induction of neuronal cell differentiation, regulator of mesenchymal to epithelial conversion during kidney development, and may also have a role in immune tolerance at the maternal-fetal interface. As its name implies, diseases associated with LIF include Leukemia and Myeloid Leukemia. Besides leukemia, increasing studies have implied that LIF also has a powerful function in cancer, such as pancreatic and breast cancer.

More interesting read related LIF>>

Popular Product

Recombinant Human Leukemia inhibitory factor(LIF) (Active) (CSB-MP012928HUd9)

Validated Data

Purity determined
by SDS-PAGE

Greater than 90% as determined by SDS-PAGE.

The binding activity of LIF-LIFR validated by functional ELISA

Immobilized human LIF at 2 μg/ml can bind human LIFR (CSB-MP012929HUi9), the EC₅₀ is 22.58-30.24 ng/ml.